Mycophenylate mofetil: what role in the treatment of lupus?
Author(s): Dooley MA Affiliation(s): Department of Medicine, Division of Rheumatology and Immunology, University of North Carolina at Chapel Hill, School of Medicine, USA. mary_dooley@med.unc.edu Publication date & source: 2006, Lupus., 15(3):179-82. Publication type: Review Improved patient survival following lupus nephritis with the institution of corticosteroids, immunosuppressants and renal replacement therapy allows greater emphasis on long-term management issues. In particular, the recent focus has been on therapies to treat nephritis with fewer adverse effects of cyclophosphamide-including immunosuppressive regimens. Mycophenolate mofetil (MMF) has been used in the field of transplantation for more than 10 years. Following initial anecdotal reports describing benefits of MMF in the treatment of lupus nephritis, randomized, controlled trials have established a role for MMF in the treatment of lupus nephritis. MMF use to treat other lupus manifestations has been evaluated only in
